Research to improve NIBRG-14, to generate a library of pandemic
candidate influenza vaccine viruses and corresponding reagents and
to test novel pandemic vaccines all feature in the IRC research
programme. IRC research is state-of-the-art and recognised
internationally; it attracts outside funding from bodies such
as:
- EU DG Research (for the rapid development of a pandemic vaccine
strain through the project FLUPAN),
- UK Medical Research Council (MRC) (for improving antigen yield
of pandemic vaccine strains),
- EU DG Research (for investigating novel pandemic vaccine
strains through the project PANFLUVAC),
- EU DG Sanco (for developing a library of pandemic strains and
reagents, on contract to project FLUSECURE).
- EU DG Research (for investigating novel pandemic vaccine
strains through the project NASPANVAC),